Fintel reports that on January 31, 2025, Canaccord Genuity downgraded their outlook for Intra-Cellular Therapies ...

Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire ...

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in ...

Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...

In a report released on January 27, Jessica Fye from J.P. Morgan maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), ...

Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.

In this article, we are going to take a look at where Intra-Cellular Therapies (NASDAQ:ITCI) stands against the other stocks. Stock gains always get people talking, and 2025 is no exception.

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...